Prostate cancer with NAT TMA
To Order Contact us: lieven@wlsolutions.be
Prostate cancer with adjacent normal prostate tissue array (2016 WHO classification) |
||
| PR243c | each | EUR 66 |
|
Description: Prostate cancer with adjacent normal prostate tissue array (2016 WHO classification), including pathology grade, TNM, clinical stage, Gleason grade and Gleason score, 12 cases/24 cores, replaced by PR243d |
||
Prostate cancer |
||
| PR632 | each | EUR 306 |
|
Description: Prostate cancer, hyperplasia with normal tissue array, including pathology grade, Gleason grade, Gleason score, TNM and clinical stage, 21cases/63 cores |
||
Prostate cancer with adjacent normal tissue and normal tissue array |
||
| PR1921c | each | EUR 594 |
|
Description: Prostate cancer with adjacent normal tissue and normal tissue array, including pathology grade, Gleason grade, Gleason score, TNM and clinical stage, PSA Marker result, 96 cases/192 cores, (core size 1.0 mm), replacing PR1921b |
||
Prostate Cancer Exosome |
||
| P141-PR | - | Ask for price |
Cancer of the prostate with progressive changes, 48 cases (1.5mm) |
||
| PRC961 | 1 | EUR 354 |
|
Description: Prostate cancer tissue array, 48 cases from hyperplastic and cancer tissues with progressive Gleason scores and TNM stages in duplicates. |
||
Polyclonal AMACR / p504S (Prostate Cancer Marker) Antibody - With BSA and Azide |
||
| APR07208G | 0.05mg | EUR 475.2 |
|
Description: A polyclonal antibody raised in Rabbit that recognizes and binds to Human AMACR / p504S (Prostate Cancer Marker) - With BSA and Azide. This antibody is tested and proven to work in the following applications: |
||
Prostate Cancer Exosome RNA |
||
| P241-PR | - | Ask for price |
LNCaP Human prostate cancer |
||
| 94A002 | Vial | EUR 375.07 |
prostate cancer Tissue block |
||
| 97 | 1 unit | EUR 625 |
Prostate cancer tissue array |
||
| BC19021a | each | EUR 306 |
|
Description: Prostate cancer tissue array, with adjacent tissue and normal tissue, including TNM and pathology grade, 28 cases/72 cores, replacing BC19021 |
||
Prostate Cancer Tissue block |
||
| 56 | 1 unit | Ask for price |
Prostate cancer Tissue block |
||
| 73 | 1 unit | EUR 465 |
Prostate cancer tissue array |
||
| PR1001 | each | EUR 306 |
|
Description: Prostate cancer tissue array, including WHO pathology grade and gleason grade, 25 cases/100 cores |
||
Prostate cancer tissue array |
||
| PR483d | each | EUR 198 |
|
Description: Prostate cancer tissue array, including TNM, clinical stage and pathology grade, with Gleason score and WHO grade, 48 cases/48 cores, replacing PR483c |
||
Prostate cancer tissue array |
||
| PR484a | each | EUR 138 |
|
Description: Prostate cancer tissue array, including WHO standerd grade, Gleason grade, Gleason score, TNM and clinical stage, 24 cases/48 cores (core size 1.5mm), replacing PR484 |
||
Prostate cancer tissue array |
||
| PR633a | each | EUR 306 |
|
Description: Prostate cancer tissue array, including TNM, clinical stage and pathology grade, 63 cases/63 cores, replacing PR633 |
||
Prostate cancer test tissue array |
||
| T195d | each | EUR 66 |
|
Description: Prostate cancer test tissue array, including TNM, Gleason score and pathology grade, 12 cases/24 cores, replaced by T195e |
||
Prostate Cancer Serum, Human Donor |
||
| MBS170265-INQUIRE | INQUIRE | Ask for price |
AMACR/p504S (Prostate Cancer Marker) |
||
| MBS439972-002mgWithBSAAzideat02mgmL | 0.02mg(WithBSA&Azideat0.2mg/mL) | EUR 230 |
AMACR/p504S (Prostate Cancer Marker) |
||
| MBS439972-01mgWithBSAAzideat02mgmL | 0.1mg(WithBSA&Azideat0.2mg/mL) | EUR 405 |
AMACR/p504S (Prostate Cancer Marker) |
||
| MBS439972-01mgWithoutBSAAzideat1mgmL | 0.1mg(WithoutBSA&Azideat1mg/mL) | EUR 405 |
AMACR/p504S (Prostate Cancer Marker) |
||
| MBS439972-5x01mgWithBSAAzideat02mgmL | 5x0.1mg(WithBSA&Azideat0.2mg/mL) | EUR 1725 |
AMACR/p504S (Prostate Cancer Marker) |
||
| MBS439972-5x01mgWithoutBSAAzideat1mgmL | 5x0.1mg(WithoutBSA&Azideat1mg/mL) | EUR 1725 |
AMACR/p504S (Prostate Cancer Marker) |
||
| MBS439974-01mL | 0.1mL | EUR 230 |
AMACR/p504S (Prostate Cancer Marker) |
||
| MBS439974-05mL | 0.5mL | EUR 405 |
AMACR/p504S (Prostate Cancer Marker) |
||
| MBS439974-5x01mL | 5x0.1mL | EUR 925 |
AMACR/p504S (Prostate Cancer Marker) |
||
| MBS4380561-002mgWithBSAAzideat02mgmL | 0.02mg(WithBSA&Azideat0.2mg/mL) | EUR 230 |
AMACR/p504S (Prostate Cancer Marker) |
||
| MBS4380561-01mgWithBSAAzideat02mgmL | 0.1mg(WithBSA&Azideat0.2mg/mL) | EUR 405 |
AMACR/p504S (Prostate Cancer Marker) |
||
| MBS4380561-01mgWithoutBSAAzideat1mgmL | 0.1mg(WithoutBSA&Azideat1mg/mL) | EUR 405 |
AMACR/p504S (Prostate Cancer Marker) |
||
| MBS4380561-5x01mgWithBSAAzideat02mgmL | 5x0.1mg(WithBSA&Azideat0.2mg/mL) | EUR 1725 |
AMACR/p504S (Prostate Cancer Marker) |
||
| MBS4380561-5x01mgWithoutBSAAzideat1mgmL | 5x0.1mg(WithoutBSA&Azideat1mg/mL) | EUR 1725 |
AMACR/p504S (Prostate Cancer Marker) |
||
| MBS4380562-002mgWithBSAAzideat02mgmL | 0.02mg(WithBSA&Azideat0.2mg/mL) | EUR 230 |
AMACR/p504S (Prostate Cancer Marker) |
||
| MBS4380562-01mgWithBSAAzideat02mgmL | 0.1mg(WithBSA&Azideat0.2mg/mL) | EUR 405 |
AMACR/p504S (Prostate Cancer Marker) |
||
| MBS4380562-01mgWithoutBSAAzideat1mgmL | 0.1mg(WithoutBSA&Azideat1mg/mL) | EUR 405 |
AMACR/p504S (Prostate Cancer Marker) |
||
| MBS4380562-5x01mgWithBSAAzideat02mgmL | 5x0.1mg(WithBSA&Azideat0.2mg/mL) | EUR 1725 |
AMACR/p504S (Prostate Cancer Marker) |
||
| MBS4380562-5x01mgWithoutBSAAzideat1mgmL | 5x0.1mg(WithoutBSA&Azideat1mg/mL) | EUR 1725 |
AMACR/p504S (Prostate Cancer Marker) |
||
| MBS4380913-002mgWithBSAAzideat02mgmL | 0.02mg(WithBSA&Azideat0.2mg/mL) | EUR 230 |
AMACR/p504S (Prostate Cancer Marker) |
||
| MBS4380913-01mgWithBSAAzideat02mgmL | 0.1mg(WithBSA&Azideat0.2mg/mL) | EUR 405 |
AMACR/p504S (Prostate Cancer Marker) |
||
| MBS4380913-01mgWithoutBSAAzideat1mgmL | 0.1mg(WithoutBSA&Azideat1mg/mL) | EUR 405 |
AMACR/p504S (Prostate Cancer Marker) |
||
| MBS4380913-5x01mgWithBSAAzideat02mgmL | 5x0.1mg(WithBSA&Azideat0.2mg/mL) | EUR 1725 |
AMACR/p504S (Prostate Cancer Marker) |
||
| MBS4380913-5x01mgWithoutBSAAzideat1mgmL | 5x0.1mg(WithoutBSA&Azideat1mg/mL) | EUR 1725 |
AMACR/p504S (Prostate Cancer Marker) |
||
| MBS4381589-002mgWithBSAAzideat02mgmL | 0.02mg(WithBSA&Azideat0.2mg/mL) | EUR 230 |
AMACR/p504S (Prostate Cancer Marker) |
||
| MBS4381589-01mgWithBSAAzideat02mgmL | 0.1mg(WithBSA&Azideat0.2mg/mL) | EUR 405 |
AMACR/p504S (Prostate Cancer Marker) |
||
| MBS4381589-01mgWithoutBSAAzideat1mgmL | 0.1mg(WithoutBSA&Azideat1mg/mL) | EUR 405 |
AMACR/p504S (Prostate Cancer Marker) |
||
| MBS4381589-5x01mgWithBSAAzideat02mgmL | 5x0.1mg(WithBSA&Azideat0.2mg/mL) | EUR 1725 |
AMACR/p504S (Prostate Cancer Marker) |
||
| MBS4381589-5x01mgWithoutBSAAzideat1mgmL | 5x0.1mg(WithoutBSA&Azideat1mg/mL) | EUR 1725 |
AMACR/p504S (Prostate Cancer Marker) |
||
| MBS4381719-002mgWithBSAAzideat02mgmL | 0.02mg(WithBSA&Azideat0.2mg/mL) | EUR 230 |
AMACR/p504S (Prostate Cancer Marker) |
||
| MBS4381719-01mgWithBSAAzideat02mgmL | 0.1mg(WithBSA&Azideat0.2mg/mL) | EUR 405 |
AMACR/p504S (Prostate Cancer Marker) |
||
| MBS4381719-01mgWithoutBSAAzideat1mgmL | 0.1mg(WithoutBSA&Azideat1mg/mL) | EUR 405 |
AMACR/p504S (Prostate Cancer Marker) |
||
| MBS4381719-5x01mgWithBSAAzideat02mgmL | 5x0.1mg(WithBSA&Azideat0.2mg/mL) | EUR 1725 |
AMACR/p504S (Prostate Cancer Marker) |
||
| MBS4381719-5x01mgWithoutBSAAzideat1mgmL | 5x0.1mg(WithoutBSA&Azideat1mg/mL) | EUR 1725 |
LNCaP Human prostate cancer - Premium |
||
| 94AP02 | Vial | EUR 535.82 |
Human Prostate Cancer Primer Library |
||
| HPRC-I | 1 set | EUR 657.6 |
Plasma - Human Prostate Cancer Patient |
||
| MBS170226-INQUIRE | INQUIRE | Ask for price |
LNCaP Human prostate cancer - Corporate |
||
| 94C002 | Vial | EUR 803.73 |
Polyclonal AMACR / p504S (Prostate Cancer Marker) Antibody - Without BSA |
||
| APR07219G | 0.1mg | EUR 580.8 |
|
Description: A polyclonal antibody raised in Rabbit that recognizes and binds to Human AMACR / p504S (Prostate Cancer Marker) - Without BSA. This antibody is tested and proven to work in the following applications: |
||
E006AA Human Prostate Cancer Cell Line |
||
| ABI-TC008D | 1 vial | Ask for price |
|
Description: E006AA is a spontaneously Immortalised cell line derived from a Gleason 6 localized prostate cancer in a hormone-naive prostate cancer patient of African American descent. This cell line grows equally well when xenografted into either intact or castrated male NOG-SCID mice and is non-tumorigenic in nude mice. E006AA should be used in parallel with E006AA-ht for modeling the early stages of prostate cancer. |
||
Single Donor Human Prostate Cancer Serum |
||
| ISERSPSTC | each | EUR 209 |
|
Description: Single Donor Human Prostate Cancer Serum |
||
Single Donor Human Prostate Cancer Serum |
||
| MBS8421626-INQUIRE | INQUIRE | Ask for price |
Single Donor Human Prostate Cancer Plasma |
||
| IPLASPSTC | each | EUR 209 |
|
Description: Single Donor Human Prostate Cancer Plasma |
||
Single Donor Human Prostate Cancer Plasma |
||
| MBS8421082-INQUIRE | INQUIRE | Ask for price |
Cancer of the prostate, 102 cases (1.5mm) |
||
| PRC1021 | 1 | EUR 354 |
|
Description: Prostate cancer tissue array, 102 cases of normal/benign (7 cases) and cancer (95 cases with grading and TNM staging data) tissues |
||
High-density prostate cancer tissue array |
||
| PR208a | each | EUR 546 |
|
Description: High-density prostate cancer tissue array, including TNM, pathology grade and Gleason score, 64 cases/192 cores, replacing PR208 |
||
AMACR / p504S Antibody (Prostate Cancer Marker) |
||
| R32468 | 100 ug | EUR 356.15 |
|
Description: Alpha-methylacyl-CoA racemase (AMACR) is a mitochondrial and peroxisomal enzyme. It encodes a racemase. The encoded enzyme interconverts pristanoyl-CoA and C27-bile acylCoAs between their (R)- and (S)-stereoisomers. The conversion to the (S)-stereoisomers is necessary for degradation of these substrates by peroxisomal beta-oxidation. Encoded proteins from this locus localize to both mitochondria and peroxisomes. Mutations in this gene may be associated with adult-onset sensorimotor neuropathy, pigmentary retinopathy, and adrenomyeloneuropathy due to defects in bile acid synthesis. Alternatively spliced transcript variants have been described. Read-through transcription also exists between this gene and the upstream neighboring C1QTNF3 (C1q and tumor necrosis factor related protein 3) gene. |
||
AMACR / p504S Antibody (Prostate Cancer Marker) |
||
| V8645-100UG | 100 ug | EUR 349.3 |
|
Description: This antibody recognizes a protein of 42kDa, which is identified as AMACR, also known as p504S. It is an enzyme that is involved in bile acid biosynthesis and -oxidation of branched-chain fatty acids. AMACR is essential in lipid metabolism. It is expressed in cells of premalignant high-grade prostatic intraepithelial neoplasia (HGPIN) and prostate adenocarcinoma. The majority of the carcinoma cells show a distinct granular cytoplasmic staining reaction. AMACR is present at low or undetectable levels in glandular epithelial cells of normal prostate and benign prostatic hyperplasia. A spotty granular cytoplasmic staining is seen in a few cells of the benign glands. AMACR is expressed in normal liver (hepatocytes), kidney (tubular epithelial cells) and gall bladder (epithelial cells). Expression has also been found in lung (bronchial epithelial cells) and colon (colonic surface epithelium). AMACR expression can also be found in hepatocellular carcinoma and kidney carcinoma. Past studies have also shown that AMACR is expressed in various colon carcinomas (well, moderately and poorly differentiated) and over expressed in prostate carcinoma. |
||
AMACR / p504S Antibody (Prostate Cancer Marker) |
||
| V8645-20UG | 20 ug | EUR 153.3 |
|
Description: This antibody recognizes a protein of 42kDa, which is identified as AMACR, also known as p504S. It is an enzyme that is involved in bile acid biosynthesis and -oxidation of branched-chain fatty acids. AMACR is essential in lipid metabolism. It is expressed in cells of premalignant high-grade prostatic intraepithelial neoplasia (HGPIN) and prostate adenocarcinoma. The majority of the carcinoma cells show a distinct granular cytoplasmic staining reaction. AMACR is present at low or undetectable levels in glandular epithelial cells of normal prostate and benign prostatic hyperplasia. A spotty granular cytoplasmic staining is seen in a few cells of the benign glands. AMACR is expressed in normal liver (hepatocytes), kidney (tubular epithelial cells) and gall bladder (epithelial cells). Expression has also been found in lung (bronchial epithelial cells) and colon (colonic surface epithelium). AMACR expression can also be found in hepatocellular carcinoma and kidney carcinoma. Past studies have also shown that AMACR is expressed in various colon carcinomas (well, moderately and poorly differentiated) and over expressed in prostate carcinoma. |
||